A PHASE 3 OPEN-LABEL STUDY OF SAFETY OF WEEKLY SUBCUTANEOUS PEGZILARGINASE IN SUBJECTS WITH ARGINASE 1 DEFICIENCY

Registry ID

CAEB1102-305

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

AEGLEA BIOTHERAPEUTICS, INC

Last update

2023-01-10

Conditions

• ARGINASE-1 DEFICIENCY

Related clinical trials

• PEACE (PEGZILARGINASE EFFECT ON ARGINASE 1 DEFICIENCY CLINICAL ENDPOINTS): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF PEGZILARGINASE IN CHILDREN AND ADULTS WITH ARGINASE 1 DEFICIENCY.
• AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFECTS OF INTRAVENOUS AEB1102 IN PATIENTS WITH ARGINASE I DEFECIENCY
• A PHASE 1/2 OPEN-LABEL STUDY IN PATIENTS WITH ARGINASE I DEFICIENCY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF INTRAVENOUS AEB1102

View on source registry